Adefovir dipivoxil

Drugs of Today

Volumn 39, Issue 2, 2003, Pages 127-135

  Buti, María ^a   Esteban, Rafael ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; COTRIMOXAZOLE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; IBUPROFEN; LAMIVUDINE; PARACETAMOL; PLACEBO;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPADNAVIRUS; HEPATITIS B; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DISORDER; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS; REVIEW; VIRUS INHIBITION; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 0037319846     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.2.799419     Document Type: Review

References (45)

1. Maddrey, W.C. Hepatitis B: An important public health issue. J Med Virol 2000, 61: 362-6.
2. Lee, W.M. Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-45.
3. Lok, A.S., Heatchote, E.J., Hoofnagle, J.H. Management of hepatitis B: Summary of a workshop. Gastroenterology 2001, 120: 1828-53.
4. Balfour, H.H.J. Antiviral drugs. N Engl J Med 1999, 340: 1255-68.
5. Chang, T.T., Lai, C.L., Liaw, Y.F. et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for fouryears. Antiviral Therapy 2000, 5 (Suppl. 1): 44.
6. Liaw, Y-F., Leung, N.W.Y., Chang, T-T. et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000, 119: 172-80.
7. Liaw, Y-F., Chien, R-N., Yeh, C-T., Tsai, S-L., Chu, C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30: 567-72.
8. Allen, M.I., Deslauriers, M., Andrews, C.W. et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27: 1670-7.
9. Perrillo, R., Rakela, J., Dienstag, J. et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999, 29: 1581-6.
10. Perrillo, R.P., Wright, T., Rakela, J. et al. A multicenter United States-Canadian trial assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33: 424-32.
11. Xiong, X., Flores, C., Fuller, M.D. et al. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (adefovir). Antiviral Res 1997, 36: 131-7.
12. Srinivas, R.V., Robbins, B.L., Connelly, M.C., Gong, Y-F., Bischofberger, N., Fridland, A. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxyrnethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother 1993, 37: 2247-50.
13. Robbins, B.L., Greenhaw, J.J., Connelly, M.C., Fridland, A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 1995, 39: 2304-8.
14. Balzarini, J., De Clercq, E. 5-Phosphoribosyl-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2 phosphonylmethoxypropyl 1-adenine and 9-(2-phosphorylmethoxyethyl) adenine directly to their antiviral active diphosphate derivatives. J Biol Chem 1991, 266: 8686-9.
15. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D.G., De Clercq, E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991, 88: 1499-503.
16. Cherrington, J.M., Allen, S.J.W., Bischofberger, N., Chen, M.S. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma. Antivir Chem Chemother 1995, 6: 217-21.
17. Xiong, X., Flores, C., Yang, H., Toole, L.L., Gibbs, C.S. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28: 1669-73.
18. Heijtink, R.A., Kruining, J., de Wilde, G.A., Balzarini, J., De Clercq, E., Schalrn, S.W. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chermother 1994, 38: 2180-2.
19. Dandri, M., Burda, M.M. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000, 32: 139-46.
20. Delmas, J., Schorr, O., Jamard, C. et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002, 46: 425-33.
21. Colledge, D., Civitico, G., Locamini, S., Shaw, T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000, 44: 551-60.
22. Melegari, M., Scaglioni, P.P., Wands, J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication detective. Hepatology 1998, 27: 628-33.
23. Ying, C., De Clercq, E., Nicholson, W., Furman, P., Neyts, L. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000, 7: 161-5.
24. Nicoll, A.J., Colledge, D.L., Toole, L.L., Angus, P.W., Smallwood, R.A., Locarnini, S.A. Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998, 42: 3130-5.
25. Cullen, L.M., Li, D.H., Brown, C. et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001, 45: 2740-5.
26. De Clercq, E., Holy, A., Rosenberg, I., Sakuma, T., Balzarini, J., Maudgal, P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323: 464-7.
27. Gilson, R.J., Chopra, K.B., Newell, A.M. et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1999, 6: 387-95.
28. Marcellin, P., Goodman, Z., Chang, T.T. et al. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. J Hepatol 2002, 36 (Suppl. 1): 8.
29. Marcellin, P., Chang, T.T., Lim, S.G. et al. GS-98-437: A double blind, randomized, placebocontrolled study of adefovir dipivoxil for the treatment of patients HBeAg chronic hepatitis B infection 48 week results. Hepatology 2001, 34: 340A
30. Marcellin, P., Chang, T.T., Lim, S.G. et al. Adefovir dipivoxil 10 mg for the treatment of patients with HBeAg chronic hepatitis B: Continued efficacy beyond 48 weeks. Hepatolgy 2002, 36: 373A.
31. Yang, H., Westland, C., Delaney, W.E. et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir for up to 60 weeks. Hepatology 2002, 36: 464-73.
32. Heatchote, E., Jeffers, L., Perrillo, R. et al. Sustained antiviral response and lack of resistance with long-term adefovir dipivoxil therapy in chronic HBV infection. J Hepatol 2002, 36 (Suppl. 1): 110-1.
33. Hadziyannis, S., Tassopoulos, N., Heatchote, J. et al. GS-98-438 - A double-blind, randomized, placebo-controlled study of adefovir dipivoxil for presumed precore mutant chronic hepatitis B: 48 weeks results. J Hepatol 2002, 36 (Suppl. 1): 4.
34. Locarnini, S.A. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance. Hepatology 1998, 27: 294-7.
35. Perillo, R., Schiff, E., Hann, H-W.L. et al. The addition of adefovir dipivoxyl to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine, preliminary 24 weeks results. Hepatology 2001, 34: 349A.
36. Westland, C.E., Yang, H., Namini, H. et al. Comparison of anti-HBV activity and adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology 2001, 34: 446A.
37. Westland, C., Gibbs, C., Miller, M. et al. Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy. J Hepatol 2002, 36 (Suppl. 1): 7.
38. Perrillo, R., Schiff, E., Yoshida, E. et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000, 32: 129-34.
39. Peters, M.G., Singer, G., Howard, T. et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999, 68: 1912-4.
40. Peters, M., Hann, H.W., Martin, P. et al. Adefovir dipivoxil alone and in combination with lamivudine suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. Hepatology 2002, 36: 374A.
41. Schiff, E., Lai, C.L., Nehaus, P. et al. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation with lamivudine-resistant hepatitis B virus patients. Hepatology 2002, 36: 371A.
42. Kahn, J., Lagakos, S., Wulfsohn, M. et al. Efficacy and safety of adefovir dipivoxil with anti-retroviral therapy: A randomized controlled trial. JAMA 1999, 282: 2305-12.
43. Barditch-Crovo, P., Toole, L., Hendrix, C.W. et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997, 176: 406-13.
44. Benhamou, Y., Bochet, M., Thibault, V. et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001, 358: 718-23.
45. Benhamou, Y., Bochet, M., Tibault, V. et al. Safety and efficacy of adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients. Hepatology 2001, 34: 319A.